Lantheus (LNTH) 10-Q 28 Jul 21 2021 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Jun. 30, 2021	Jul. 23, 2021
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2021
Document Transition Report	false
Entity File Number	001-36569
Entity Registrant Name	LANTHEUS HOLDINGS, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	35-2318913
Entity Address, Address Line One	331 Treble Cove Road
Entity Address, Postal Zip Code	01862
Entity Address, City or Town	North Billerica,
Entity Address, State or Province	MA
City Area Code	(978)
Local Phone Number	671-8001
Title of 12(b) Security	Common stock, par value $0.01 per share
Trading Symbol	LNTH
Security Exchange Name	NASDAQ
Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		67,604,097
Amendment Flag	false
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Entity Central Index Key	0001521036
Current Fiscal Year End Date	--12-31

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 91,500	$ 79,612
Accounts receivable, net	54,892	54,002
Inventory	31,719	35,744
Other current assets	8,102	9,625
Assets held for sale	0	5,242
Total current assets	186,213	184,225
Property, plant and equipment, net	118,493	120,171
Intangibles, net	365,259	376,012
Goodwill	61,189	58,632
Deferred tax assets, net	64,777	70,147
Other long-term assets	61,871	60,634
Total assets	857,802	869,821
Current liabilities
Current portion of long-term debt and other borrowings	10,372	20,701
Accounts payable	21,471	16,284
Accrued expenses and other liabilities	41,983	41,726
Liabilities held for sale	0	1,793
Total current liabilities	73,826	80,504
Asset retirement obligations	14,797	14,020
Long-term debt, net and other borrowings	169,249	197,699
Other long-term liabilities	91,790	63,393
Total liabilities	349,662	355,616
Commitments and contingencies (See Note 18)
Stockholders’ equity
Preferred stock ($0.01 par value, 25,000 shares authorized; no shares issued and outstanding)	0	0
Common stock ($0.01 par value, 250,000 shares authorized; 67,592 and 66,875 shares issued and outstanding, respectively)	676	669
Additional paid-in capital	676,059	665,530
Accumulated deficit	(167,595)	(149,946)
Accumulated other comprehensive loss	(1,000)	(2,048)
Total stockholders’ equity	508,140	514,205
Total liabilities and stockholders’ equity	$ 857,802	$ 869,821

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	25,000,000	25,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	250,000,000	250,000,000
Common stock, shares issued (in shares)	67,592,000	66,875,000
Common stock, shares outstanding (in shares)	67,592,000	66,875,000
Goodwill	$ 61,189	$ 58,632

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Income Statement [Abstract]
Revenues	$ 101,064	$ 66,010	$ 193,573	$ 156,714
Cost of goods sold	54,976	40,162	106,455	92,864
Gross profit	46,088	25,848	87,118	63,850
Operating expenses
Sales and marketing	17,631	6,305	31,804	16,435
General and administrative	43,177	20,670	59,315	37,369
Research and development	12,061	4,418	22,421	8,466
Total operating expenses	72,869	31,393	113,540	62,270
Gain on sale of assets	0	0	15,263	0
Operating (loss) income	(26,781)	(5,545)	(11,159)	1,580
Interest expense	1,937	1,914	4,655	3,860
Gain on extinguishment of debt	0	0	(889)	0
Other income	(182)	(756)	(731)	(1,106)
Loss before income taxes	(28,536)	(6,703)	(14,194)	(1,174)
Income tax (benefit) expense	(1,879)	309	3,455	2,501
Net loss	$ (26,657)	$ (7,012)	$ (17,649)	$ (3,675)
Net loss per common share:
Basic (in dollars per share)	$ (0.39)	$ (0.16)	$ (0.26)	$ (0.09)
Diluted (in dollars per share)	$ (0.39)	$ (0.16)	$ (0.26)	$ (0.09)
Weighted-average common shares outstanding:
Basic (in shares)	67,505	43,135	67,300	41,284
Diluted (in shares)	67,505	43,135	67,300	41,284

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Statement of Comprehensive Income [Abstract]
Net loss	$ (26,657)	$ (7,012)	$ (17,649)	$ (3,675)
Other comprehensive income (loss):
Foreign currency translation	194	252	296	(194)
Unrealized gain (loss) on cash flow hedges, net of tax	46	(464)	752	(1,452)
Total other comprehensive income (loss)	240	(212)	1,048	(1,646)
Comprehensive loss	$ (26,417)	$ (7,224)	$ (16,601)	$ (5,321)

Condensed Consolidated Changes

Condensed Consolidated Changes In Stockholders' Equity (Statement) - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss
Beginning balance (in shares) at Dec. 31, 2019		39,251
Beginning balance at Dec. 31, 2019	$ 114,601	$ 393	$ 251,641	$ (136,473)	$ (960)
Net income (loss)	3,337			3,337
Other comprehensive income (loss)	(1,434)				(1,434)
Stock option exercises and employee stock plan purchases (in shares)		33
Stock option exercises and employee stock plan purchases	366		366
Vesting of restricted stock awards and units (in shares)		563
Vesting of restricted stock awards and units	0	$ 6	(6)
Shares withheld to cover taxes (in shares)		(97)
Shares withheld to cover taxes	(1,547)	$ (1)	(1,546)
Stock-based compensation	3,075		3,075
Ending balance (in shares) at Mar. 31, 2020		39,750
Ending balance at Mar. 31, 2020	118,398	$ 398	253,530	(133,136)	(2,394)
Beginning balance (in shares) at Dec. 31, 2019		39,251
Beginning balance at Dec. 31, 2019	114,601	$ 393	251,641	(136,473)	(960)
Net income (loss)	(3,675)
Other comprehensive income (loss)	(1,646)
Ending balance (in shares) at Jun. 30, 2020		66,808
Ending balance at Jun. 30, 2020	515,583	$ 668	657,669	(140,148)	(2,606)
Beginning balance (in shares) at Mar. 31, 2020		39,750
Beginning balance at Mar. 31, 2020	118,398	$ 398	253,530	(133,136)	(2,394)
Net income (loss)	(7,012)			(7,012)
Other comprehensive income (loss)	(212)				(212)
Stock option exercises and employee stock plan purchases (in shares)		7
Stock option exercises and employee stock plan purchases	50		50
Vesting of restricted stock awards and units (in shares)		242
Vesting of restricted stock awards and units	0	$ 2	(2)
Shares withheld to cover taxes (in shares)		(36)
Shares withheld to cover taxes	(485)	$ (1)	(484)
Issuance of common stock (in shares)		26,845
Issuance of common stock, net of $3,776 issuance costs	394,334	$ 269	394,065
Fair value of replacement options related to pre-acquisition services	7,125		7,125
Stock-based compensation	3,385		3,385
Ending balance (in shares) at Jun. 30, 2020		66,808
Ending balance at Jun. 30, 2020	515,583	$ 668	657,669	(140,148)	(2,606)
Beginning balance (in shares) at Dec. 31, 2020		66,875
Beginning balance at Dec. 31, 2020	514,205	$ 669	665,530	(149,946)	(2,048)
Net income (loss)	9,008			9,008
Other comprehensive income (loss)	808				808
Stock option exercises and employee stock plan purchases (in shares)		155
Stock option exercises and employee stock plan purchases	2,380	$ 1	2,379
Vesting of restricted stock awards and units (in shares)		489
Vesting of restricted stock awards and units	0	$ 5	(5)
Shares withheld to cover taxes (in shares)		(85)
Shares withheld to cover taxes	(1,599)	$ (1)	(1,598)
Stock-based compensation	3,317		3,317
Ending balance (in shares) at Mar. 31, 2021		67,434
Ending balance at Mar. 31, 2021	528,119	$ 674	669,623	(140,938)	(1,240)
Beginning balance (in shares) at Dec. 31, 2020		66,875
Beginning balance at Dec. 31, 2020	514,205	$ 669	665,530	(149,946)	(2,048)
Net income (loss)	(17,649)
Other comprehensive income (loss)	1,048
Ending balance (in shares) at Jun. 30, 2021		67,592
Ending balance at Jun. 30, 2021	508,140	$ 676	676,059	(167,595)	(1,000)
Beginning balance (in shares) at Mar. 31, 2021		67,434
Beginning balance at Mar. 31, 2021	528,119	$ 674	669,623	(140,938)	(1,240)
Net income (loss)	(26,657)			(26,657)
Other comprehensive income (loss)	240				240
Stock option exercises and employee stock plan purchases (in shares)		116
Stock option exercises and employee stock plan purchases	2,043	$ 1	2,042
Vesting of restricted stock awards and units (in shares)		51
Vesting of restricted stock awards and units	0	$ 1	(1)
Shares withheld to cover taxes (in shares)		(9)
Shares withheld to cover taxes	(193)		(193)
Stock-based compensation	4,588		4,588
Ending balance (in shares) at Jun. 30, 2021		67,592
Ending balance at Jun. 30, 2021	$ 508,140	$ 676	$ 676,059	$ (167,595)	$ (1,000)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Operating activities
Net income (loss)	$ (17,649)	$ (3,675)
Adjustments to reconcile net loss to net cash flows from operating activities:
Depreciation, amortization and accretion	17,749	7,764
Impairment of long-lived assets	0	7,275
Amortization of debt related costs	185	338
Changes in fair value of contingent assets and liabilities	25,900	0
Gain on extinguishment of debt	(889)	0
Provision for excess and obsolete inventory	2,039	1,531
Stock-based compensation	7,905	6,460
Gain on sale of assets	(15,263)	0
Deferred taxes	2,685	1,067
Long-term income tax receivable	(731)	(1,109)
Long-term income tax payable and other long-term liabilities	1,147	1,409
Other	1,097	614
Increases (decreases) in cash from operating assets and liabilities:
Accounts receivable	1,551	2,087
Inventory	1,888	(6,777)
Other current assets	2,171	1,742
Accounts payable	5,888	(3,452)
Accrued expenses and other liabilities	14	(8,022)
Net cash provided by operating activities	35,687	7,252
Investing activities
Capital expenditures	(5,176)	(4,953)
Proceeds from sale of assets, net	15,823	0
Lending on bridge loan	0	(10,000)
Cash acquired in acquisition of business	0	17,562
Net cash provided by investing activities	10,647	2,609
Financing activities
Payments on long-term debt and other borrowings	(38,137)	(7,032)
Equity issuance costs	0	(345)
Deferred financing costs	0	(1,225)
Proceeds from stock option exercises	4,086	50
Proceeds from issuance of common stock	337	366
Payments for minimum statutory tax withholding related to net share settlement of equity awards	(1,792)	(2,032)
Net cash used in financing activities	(35,506)	(10,218)
Effect of foreign exchange rates on cash, cash equivalents and restricted cash	120	(112)
Net increase (decrease) in cash, cash equivalents and restricted cash	10,948	(469)
Cash, cash equivalents and restricted cash, beginning of period	82,694	92,919
Cash, cash equivalents and restricted cash, end of period	93,642	92,450
Reconciliation to amounts within the condensed consolidated balance sheets
Cash and cash equivalents	91,500	90,309
Restricted cash included in other long-term assets	2,142	2,141
Cash, cash equivalents and restricted cash at end of period	$ 93,642	$ 92,450

Condensed Consolidated Change_2

Condensed Consolidated Changes In Stockholders' Equity (Parenthetical) $ in Thousands	3 Months Ended
	Jun. 30, 2020USD ($)
Statement of Stockholders' Equity [Abstract]
Issuance costs	$ 3,776

Basis of Presentation

Basis of Presentation	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements include the accounts of Holdings and its direct and indirect wholly-owned subsidiaries, including Progenics (as of the Closing Date, as defined below), and have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these condensed consolidated financial statements do not include all of the information and notes required by generally accepted accounting principles in the United States of America (“U.S. GAAP”) for complete financial statements. In the opinion of management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement have been included. The results of operations for the three and six months ended June 30, 2021 are not necessarily indicative of the results that may be expected for the year ended December 31, 2021 or any future period. In the first quarter of fiscal year 2021, the Company completed the evaluation of its operating and reporting structure, which resulted in a change in operating segments. Please refer to Note 19, “Segment Information”, for further details. The condensed consolidated balance sheet at December 31, 2020 has been derived from the audited consolidated financial statements at that date but does not include all the information and notes required by U.S. GAAP for complete financial statements. These condensed consolidated financial statements and accompanying notes should be read in conjunction with the consolidated financial statements and notes thereto included in Item 8 of the Company’s most recent Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities Exchange Commission (“SEC”) on February 25, 2021. Progenics Acquisition On June 19, 2020 (the “Closing Date”), pursuant to the Amended and Restated Agreement and Plan of Merger, dated as of February 20, 2020 (the “Merger Agreement”), by and among Holdings, Plato Merger Sub, Inc., a wholly-owned subsidiary of Holdings (“Merger Sub”), and Progenics, Holdings completed the previously announced acquisition of Progenics by means of a merger of Merger Sub with and into Progenics, with Progenics surviving such merger as a wholly-owned subsidiary of Holdings (the “Progenics Acquisition”). In accordance with the Merger Agreement, at the effective time of the Progenics Acquisition (the “Effective Time”), each share of Progenics common stock, par value $0.0013 per share, issued and outstanding immediately prior to the Effective Time (other than shares of Progenics common stock owned by Holdings, Progenics or any of their wholly-owned subsidiaries) was automatically cancelled and converted into the right to receive (i) 0.31 (the “Exchange Ratio”) of a share of Holdings common stock, par value $0.01 per share, and (ii) one contingent value right (a “CVR”) tied to the financial performance of PyL (18F-DCFPyL), Progenics’ prostate-specific membrane antigen (“PSMA”) targeted imaging agent designed to visualize prostate cancer. This agent was approved by the U.S. Food and Drug Administration (“FDA”) on May 26, 2021 under the name PYLARIFY (piflufolastat F 18), and the commercial launch of this agent has begun. Each CVR will entitle its holder to receive a pro rata share of aggregate cash payments equal to 40% of U.S. net sales generated by PYLARIFY in 2022 and 2023 in excess of $100.0 million and $150.0 million, respectively. In no event will the Company’s aggregate payments in respect of the CVRs, together with any other non-stock consideration treated as paid in connection with the Progenics Acquisition, exceed 19.9% (which the Company estimates could be approximately $100.0 million) of the total consideration the Company pays in the Progenics Acquisition. No fractional shares of Holdings common stock were issued in the Progenics Acquisition, and Progenics’ former stockholders have received cash in lieu of any fractional shares of Holdings common stock. As a result of the acquisition, Holdings issued 26,844,877 shares of Holdings common stock and 86,630,633 CVRs to former Progenics stockholders. Please refer to Note 8, “Business Combinations”, for further details on the acquisition. COVID-19 The Company experienced operational and financial impacts from the COVID-19 pandemic beginning late in the first quarter of 2020 and through the date of this filing, including the impact of stay-at-home mandates and advisories, and a decline in the volume of certain procedures and treatments using the Company’s products. For example, there has been a substantial reduction in pulmonary ventilation studies in which the Company’s product, Xenon, is used. As a result of the COVID-19 pandemic, the Company undertook a thorough analysis of all its discretionary expenses. In the first quarter of 2020, the Company implemented certain cost reduction initiatives. For most of the second quarter of 2020, the Company reduced the Company’s work week from five days to four days and reduced the pay for employees by varying amounts depending on level of seniority. During the second quarter of 2020, Progenics also implemented certain cost reduction initiatives and paused new enrollment in the Phase 2 trial of 1095 in metastatic castrate-resistant prostate cancer (“mCRPC”) patients to minimize the risk to subjects and healthcare providers during the pandemic. New enrollment in that study restarted in October 2020. GE Healthcare Limited (“GE Healthcare”), the Company’s development and commercialization partner for flurpiridaz fluorine-18 (“F 18”), also delayed enrollment in the second Phase 3 clinical trial of flurpiridaz F 18 because of the pandemic and resumed enrollment in the third quarter of 2020. Although the COVID-19 pandemic appears to have begun to recede in much of the United States, the pandemic could still have a future negative impact on the Company's business, particularly if there is a resurgence as a result of mutations or other variations to the virus that increase its communicability or its impact on certain populations. While the impact of COVID-19 on the Company’s results of operations and cash flows has been material, given continued uncertainty about the future trajectory of the pandemic, the Company remains unable to accurately predict the impact of COVID-19 on its overall 2021 operations and financial results or cash flows and whether the on-going impact of COVID-19 could lead to potential future impairments.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Reclassifications Certain immaterial reclassifications in the prior period consolidated statement of cash flows have been reclassified to conform to the current year period financial statement presentation. Reclassifications include $0.2 million from provision for bad debt to other at June 30, 2020. The Company had a reclassification in presentation related to rebates and allowances within product revenue. Please refer to Note 3, “Revenue from Contracts with Customers” for further details. Recent Accounting Pronouncements Standard Description Effect on the Condensed Consolidated Financial Statements Accounting Standards Adopted During the Six Months Ended June 30, 2021 ASU 2020-06, “Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40)” This ASU provides guidance to simplify the complexity associated with accounting for convertible instruments and derivatives. For convertible instruments, the number of major separation models required were reduced. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. This ASU further amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. The ASU simplifies the diluted net income per share calculation in certain areas as well. January 1, 2021 The adoption of this standard did not have a material impact on the Company’s condensed consolidated financial statements.

Revenue from Contracts with Cus

Revenue from Contracts with Customers	6 Months Ended
	Jun. 30, 2021
Revenue from Contract with Customer [Abstract]
Revenue from Contracts with Customers	Revenue from Contracts with Customers The following table summarizes revenue by revenue source as follows: Three Months Ended Six Months Ended Major Products/Service Lines (in thousands) 2021 2020 2021 2020 Product revenue, net (1) $ 93,562 $ 64,927 $ 180,881 $ 155,140 License and royalty revenues 7,502 1,083 12,692 1,574 Total revenues $ 101,064 $ 66,010 $ 193,573 $ 156,714 ________________________________ (1) The Company’s principal products include DEFINITY and TechneLite and are categorized within product revenue, net. The Company applies the same revenue recognition policies and judgments for all its principal products. The Company classifies its revenues into three product categories: precision diagnostics, radiopharmaceutical oncology, and strategic partnerships and other. Precision diagnostics includes DEFINITY, TechneLite and other imaging diagnostic products. Radiopharmaceutical oncology consists primarily of AZEDRA and PYLARIFY. Strategic partnerships and other includes partnerships related to other products, such as RELISTOR, that improve patient outcomes and care. Revenue by product category on a net basis is as follows: Three Months Ended Six Months Ended (in thousands) 2021 2020 (1) 2021 2020 (1) DEFINITY $ 59,842 $ 37,125 $ 115,813 $ 89,630 TechneLite 23,772 18,668 46,572 41,447 Other precision diagnostics 6,742 7,140 13,726 20,197 Total precision diagnostics 90,356 62,933 176,111 151,274 Radiopharmaceutical oncology 2,812 2,183 4,312 4,151 Strategic partnerships and other 7,896 894 13,150 1,289 Total revenues $ 101,064 $ 66,010 $ 193,573 $ 156,714 ________________________________ (1) The Company reclassified rebates and allowances of $3.5 million and $8.2 million within each product category, which included $3.2 million and $7.5 million for DEFINITY, $0.3 million and $0.6 million for TechneLite and zero and $0.1 million for other precision diagnostics, for the three and six months ended June 30, 2020, respectively. The Company’s performance obligations are typically part of contracts that have an original expected duration of one year or less. As such, the Company is not disclosing the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied (or partially satisfied) as of the end of the reporting period.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	6 Months Ended
	Jun. 30, 2021
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability of fair value measurements, financial instruments are categorized based on a hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below: • Level 1 — Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. • Level 2 — Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves, etc.) and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs). • Level 3 — Unobservable inputs that reflect a Company’s estimates about the assumptions that market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available, including its own data. The Company’s financial assets and liabilities measured at fair value on a recurring basis consist of money market funds, interest rate swaps, a contingent receivable and contingent consideration liabilities. The Company invests excess cash from its operating cash accounts in overnight investments and reflects these amounts in cash and cash equivalents in the condensed consolidated balance sheets at fair value using quoted prices in active markets for identical assets. The fair value of the interest rate swaps is determined based on observable market-based inputs, including interest rate curves and reflects the contractual terms of these instruments, including the period to maturity. Please refer to Note 13, “Derivative Instruments”, for further details on the interest rate swaps. The Company recorded a contingent receivable and the contingent consideration liabilities resulting from the Progenics Acquisition at fair value based on inputs that are not observable in the market. Please refer to Note 8, “Business Combinations”, for further details on the acquisition. The tables below present information about the Company’s assets and liabilities measured at fair value on a recurring basis: June 30, 2021 (in thousands) Total Fair Level 1 Level 2 Level 3 Assets: Money market $ 38,547 $ 38,547 $ — $ — Contingent receivable 13,400 — — 13,400 Total assets $ 51,947 $ 38,547 $ — $ 13,400 Liabilities: Interest rate swaps $ 897 $ — $ 897 $ — Contingent consideration liabilities 43,800 — — 43,800 Total liabilities $ 44,697 $ — $ 897 $ 43,800 December 31, 2020 (in thousands) Total Fair Level 1 Level 2 Level 3 Assets: Money market $ 35,457 $ 35,457 $ — $ — Contingent receivable 11,300 — — 11,300 Total assets $ 46,757 $ 35,457 $ — $ 11,300 Liabilities: Interest rate swaps $ 1,908 $ — $ 1,908 $ — Contingent consideration liabilities 15,800 — — 15,800 Total liabilities $ 17,708 $ — $ 1,908 $ 15,800 During the three and six months ended June 30, 2021, there were no transfers into or out of Level 3. As part of the Progenics Acquisition, the Company acquired the right to receive certain future milestone and royalty payments due to Progenics from CytoDyn Inc. related to a prior sale of certain intellectual property. The Company has the right to receive $5.0 million upon regulatory approval and a 5% royalty on net sales of approved products. The Company considers the contingent receivable a Level 3 instrument (one with significant unobservable inputs) in the fair value hierarchy. The estimated fair value was determined based on probability adjusted discounted cash flows that included significant estimates and assumptions pertaining to regulatory events and sales targets. The most significant unobservable inputs are the probabilities of achieving regulatory approval of the development projects and subsequent commercial success. As part of the Progenics Acquisition, the Company issued CVRs and recorded the fair value as part of consideration transferred. Refer to Note 1, “Basis of Presentation” for further details on the CVRs. Additionally, the Company assumed contingent consideration liabilities related to a previous acquisition completed by Progenics in 2013 (“2013 Acquisition”). These contingent consideration liabilities include potential payments of up to $70.0 million if the Company attains certain net sales targets primarily for AZEDRA and 1095 and a $5.0 million 1095 commercialization milestone. Additionally, there is a potential payment of up to $10.0 million related to a 1404 commercialization milestone. The Company’s total potential payments related to the 2013 Acquisition are approximately $85.0 million. The Company considers the contingent consideration liabilities relating to the CVRs and the 2013 Acquisition, each a Level 3 instrument (one with significant unobservable inputs) in the fair value hierarchy. The estimated fair value of these was determined based on probability adjusted discounted cash flows and Monte Carlo simulation models that included significant estimates and assumptions pertaining to commercialization events and sales targets. The most significant unobservable inputs are the probabilities of achieving regulatory approval of the development projects and subsequent commercial success. Significant changes in any of the probabilities of success, the probabilities as to the periods in which milestones will be achieved, discount rates or underlying revenue forecasts would result in a significantly higher or lower fair value measurement. The Company records the contingent consideration liability at fair value with changes in estimated fair values recorded in general and administrative expenses in the condensed consolidated statements of operations. The Company can give no assurance that the actual amounts paid, if any, in connection with the contingent consideration liabilities, including the CVRs, will be consistent with any recurring fair value estimate of such contingent consideration liabilities. The following tables summarize quantitative information and assumptions pertaining to the fair value measurement of assets and liabilities using Level 3 inputs at June 30, 2021. Fair Value at Assumptions (in thousands) June 30, 2021 December 31, 2020 Valuation Technique Unobservable Input June 30, 2021 December 31, 2020 Contingent receivable: Regulatory milestone $ 3,300 $ 3,200 Probability adjusted discounted cash flow model Period of expected milestone achievement 2022 2021 Probability of success 90 % 90 % Discount rate 18 % 24 % Royalties 10,100 8,100 Probability adjusted discounted cash flow model Probability of success 13% - 77% 13% - 77% Discount rate 18 % 24 % Total $ 13,400 $ 11,300 Fair Value at Assumptions (in thousands) June 30, 2021 December 31, 2020 Valuation Technique Unobservable Input June 30, 2021 December 31, 2020 Contingent consideration liability: Net sales targets - PYLARIFY (CVRs) $ 30,400 $ 4,200 Monte-Carlo simulation Period of expected milestone achievement 2022 - 2023 2022 - 2023 Discount rate 18 % 24 % 1095 commercialization milestone 1,900 2,200 Probability adjusted discounted cash flow model Period of expected milestone achievement 2026 2026 Probability of success 40 % 45 % Discount rate 0.9 % 0.5 % Net sales targets - AZEDRA and 1095 11,500 9,400 Monte-Carlo simulation Probability of success 40% - 100% 40% - 100% Discount rate 17% - 18% 23% - 24% Total $ 43,800 $ 15,800 For those financial instruments with significant Level 3 inputs, the following table summarizes the activities for the periods indicated: Financial Assets Financial Liabilities (in thousands) Six Months Ended Six Months Ended 2021 2020 2021 2020 Fair value, beginning of period $ 11,300 $ — $ 15,800 $ — Progenics acquisition — 10,100 — 16,300 Changes in fair value included in net loss 2,100 — 28,000 — Fair value, end of period $ 13,400 $ 10,100 $ 43,800 $ 16,300 The change in fair value of the contingent financial asset and contingent financial liabilities, including the CVRs, resulted in an expense of $25.9 million for the six months ended June 30, 2021 and was primarily due to changes in revenue forecasts, changes in market conditions, a decrease in discount rates and the passage of time.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company provides for income taxes at the end of each interim period based on the estimated effective tax rate for the full year, adjusted for any discrete events which are recorded in the period they occur. Cumulative adjustments to the tax provision are recorded in the interim period in which a change in the estimated annual effective tax rate is determined. The Company’s income tax expense is presented below: Three Months Ended Six Months Ended (in thousands) 2021 2020 2021 2020 Income tax (benefit) expense $ (1,879) $ 309 $ 3,455 $ 2,501 The Company regularly assesses its ability to realize its deferred tax assets. Assessing the realizability of deferred tax assets requires significant management judgment. In determining whether its deferred tax assets are more-likely-than-not realizable, the Company evaluated all available positive and negative evidence, and weighed the objective evidence and expected impact. The Company assessed the need for a valuation allowance against certain state tax credit carryforwards added through the Progenics Acquisition. The Company continues to record other valuation allowances of $1.2 million against the net deferred tax assets of its U.K. subsidiary, and $2.2 million against the net deferred tax assets of its Sweden subsidiary. In connection with the Company’s acquisition of the medical imaging business from Bristol-Myers Squibb (“BMS”) in 2008, the Company recorded a liability for uncertain state tax positions related to the acquired business and simultaneously entered into a tax indemnification agreement with BMS under which BMS agreed to indemnify the Company for any payments made to settle those uncertain tax positions with the state taxing authorities. Accordingly, a long-term receivable is recorded to account for the expected value to the Company of future indemnification payments to be paid on behalf of the Company by BMS, net of actual tax benefits received by the Company. The tax indemnification receivable is recorded within other long-term assets. In accordance with the Company’s accounting policy, the change in the tax liabilities, penalties and interest associated with these obligations (net of any offsetting federal or state benefit) is recognized within income tax expense. As these reserves change, adjustments are included in income tax expense while the offsetting adjustment is included in other income. Assuming that the receivable from BMS continues to be considered recoverable by the Company, there will be no effect on net income and no net cash outflows related to these liabilities. For the three and six months ended June 30, 2021, the Company released $0.7 million of liabilities for uncertain tax positions, including interest and penalties of $0.5 million. This included a release of liabilities of $0.5 million, including interest and penalties of $0.4 million, due to a change in estimate with respect to the Company’s indemnified uncertain tax positions arising from an effective settlement during the year. The remaining release of $0.2 million of liability was due to the lapse of a statute of limitations. On June 19, 2020, the Company completed the Progenics Acquisition in a transaction that is expected to qualify as a tax-deferred reorganization under Section 368 of the Internal Revenue Code. The transaction resulted in an ownership change of Progenics under Section 382 of the Internal Revenue Code and a limitation on the utilization of Progenics’ precombination tax attributes. All of Progenics’ precombination federal research and Orphan drug credits have been removed from the balance sheet, and the gross carrying value of the tax loss carryforwards reduced to their realizable value on the opening balance sheet, in accordance with the Section 382 limitation. Deferred tax liabilities arising from the purchase accounting basis step-up in identified intangibles were recorded at acquisition, resulting in an initial net overall deferred tax liability for Progenics after the application of acquisition accounting.

Inventory

Inventory	6 Months Ended
	Jun. 30, 2021
Inventory Disclosure [Abstract]
Inventory	Inventory Inventory consisted of the following: (in thousands) June 30, December 31, Raw materials $ 14,578 $ 16,000 Work in process 11,687 11,212 Finished goods 5,454 8,532 Total inventory $ 31,719 $ 35,744 Inventory costs associated with products that have not yet received regulatory approval are capitalized if the Company believes there is probable future commercial use of the product and future economic benefit of the asset. If future commercial use of the product is not probable, then inventory costs associated with such product are expensed during the period the costs are incurred. As of June 30, 2021, the Company had $2.6 million of such product costs included in inventories related to DEFINITY that have been manufactured through the Company’s in-house manufacturing capabilities, which is awaiting regulatory approval.

Property, Plant and Equipment,

Property, Plant and Equipment, Net	6 Months Ended
	Jun. 30, 2021
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment, Net	Property, Plant and Equipment, Net Property, plant and equipment, net, consisted of the following: (in thousands) June 30, December 31, Land $ 13,450 $ 13,450 Buildings 72,472 70,381 Machinery, equipment and fixtures 83,758 77,854 Computer software 24,110 23,644 Construction in progress 7,431 11,254 201,221 196,583 Less: accumulated depreciation and amortization (82,728) (76,412) Total property, plant and equipment, net $ 118,493 $ 120,171 Depreciation and amortization expense related to property, plant and equipment, net, was $3.2 million and $2.7 million for the three months ended June 30, 2021 and 2020, respectively, and $6.2 million and $5.7 million for the six months ended June 30, 2021 and 2020, respectively. The Company tests long-lived assets for recoverability whenever events or changes in circumstances suggest that the carrying value of an asset or group of assets may not be recoverable. During the three months ended March 31, 2020, as a result of a decline in expected future cash flows and the effect of COVID-19 related to certain other nuclear legacy manufacturing assets, the Company determined certain impairment triggers had occurred. Accordingly, the Company performed an undiscounted cash flow analysis as of March 31, 2020. Based on the undiscounted cash flow analysis, the Company determined that the manufacturing assets had net carrying values that exceeded their estimated undiscounted future cash flows. The Company then estimated the fair values of the asset group based on their discounted cash flows. The carrying value exceeded the fair value and as a result, the Company recorded a non-cash impairment of $7.3 million for the six months ended June 30, 2020 in cost of goods sold in the condensed consolidated statement of operations.

Business Combinations

Business Combinations	6 Months Ended
	Jun. 30, 2021
Business Combination and Asset Acquisition [Abstract]
Business Combinations	Business Combinations On June 19, 2020, the Company completed the Progenics Acquisition. The acquisition combined the commercialization, supply chain and manufacturing expertise of the Company with the currently commercialized products and research and development (“R&D”) pipeline of Progenics. Progenics brought to the Company several commercial products and a pipeline of product candidates that further diversify the Company’s commercial and clinical development portfolios. Under the terms of the Merger Agreement, the Company acquired all the issued and outstanding shares of Progenics common stock for a purchase price of $419.0 million by means of an all-stock transaction, which includes options to purchase Holdings common stock (“Replacement Stock Options”) for precombination services as well as CVRs. The CVRs were accounted for as contingent consideration, the fair value of which was determined using a Monte-Carlo simulation. Additionally, the fair value of Replacement Stock Options related to precombination services was recorded as a component of consideration transferred. Finally, as a result of the acquisition, Lantheus effectively settled an existing bridge loan with Progenics at the recorded amount (principal and accrued interest) of $10.1 million, representing the effective settlement of a preexisting relationship. This effective settlement of the bridge loan was treated as a component of consideration transferred. The Company determined that the bridge loan was at market terms and no gain or loss was recorded upon settlement. The acquisition date fair value of the consideration transferred in the acquisition consisted of the following: (in thousands) Amount Issuance of common stock $ 398,110 Fair value of replacement options 7,125 Fair value of bridge loan settled at close 10,074 Fair value of contingent considerations (CVRs) 3,700 Total consideration transferred (1) $ 419,009 (1) Non-cash investing and financing activities in the condensed consolidated statements of cash flows The transaction was accounted for as a business combination which requires that assets acquired and liabilities assumed be recognized at their fair value as of the acquisition date. While the Company uses its best estimates and assumptions as part of the purchase price allocation process to value the assets acquired and liabilities assumed on the acquisition date, its estimates and assumptions are subject to refinement. Fair value estimates are based on a complex series of judgments about future events and uncertainties and rely heavily on estimates and assumptions. The judgments used to determine the estimated fair value assigned to each class of assets acquired and liabilities assumed, as well as asset lives, can materially impact the Company’s results of operations. The Company recorded a measurement period adjustment of $2.6 million related to deferred taxes for the three months ended March 31, 2021, which finalized all measurement period adjustments related to the Progenics Acquisition. The following table summarizes the provisional amounts recognized for assets acquired and liabilities assumed as of the acquisition date, as well as measurement period adjustments made to the amounts initially recorded in June 2020. The measurement period adjustments primarily resulted from finalizing the fair values of certain intangible assets and liabilities, deferred taxes and other changes to certain tangible assets and liability accounts. Measurement period adjustments were recognized in the reporting period in which the adjustments were determined and calculated as if the accounting had been completed at the acquisition date. The related impact to net loss that would have been recognized in previous periods if the adjustments were recognized as of the acquisition date is immaterial to the consolidated financial statements. (in thousands) Amounts Recognized as of Acquisition Date Measurement Period Adjustments Amounts Recognized as of Acquisition Date Cash and cash equivalents $ 15,421 $ — $ 15,421 Accounts receivable 5,787 — 5,787 Inventory 915 160 1,075 Other current assets 3,250 434 3,684 Property, plant and equipment 14,972 — 14,972 Identifiable intangible assets (weighted average useful life): Currently marketed product (15 years) 142,100 800 142,900 Licenses (11.5 years) 87,500 (1,700) 85,800 Developed technology (9 years) 3,000 (600) 2,400 IPR&D 150,900 200 151,100 Other long-term assets 37,631 — 37,631 Accounts payable (1,616) — (1,616) Accrued expenses and other liabilities (8,207) (80) (8,287) Other long-term liabilities (30,778) (380) (31,158) Long-term debt and other borrowings (40,200) — (40,200) Deferred tax liabilities (3,717) (2,258) (5,975) Goodwill 42,051 3,424 45,475 Total consideration transferred $ 419,009 $ — $ 419,009 Intangible assets acquired consist of currently marketed products, licenses, developed technology and in-process research and development (“IPR&D”). The fair value of the acquired intangible assets was determined based on estimated future revenues, royalty rates and discount rates, among other variables and estimates. The acquired intangible assets subject to amortization were assigned useful lives based on the expected use of the assets and the regulatory and economic environment within which they are being used and are being amortized on a straight-line basis over the respective estimated useful lives. The estimated fair values of the IPR&D assets were determined based on the present values of the expected cash flows to be generated by the respective underlying assets. The Company used a discount rate of 23.0% and cash flows that have been probability adjusted to reflect the risks of product commercialization, which the Company believes are appropriate and representative of market participant assumptions. As part of the Progenics Acquisition, the Company acquired the right to receive certain future milestone and royalty payments due to Progenics, related to a prior sale of certain intellectual property. The estimated fair value of the acquired contingent receivable of $10.1 million was determined by applying a probability adjusted discounted cash flow model based on estimated future expected payments and recorded in other long-term assets. The goodwill recognized is attributable to future technologies that are not separately identifiable that could potentially add to the currently developed and pipeline products and Progenics’ assembled workforce. Future technologies did not meet the criteria for recognition separately from goodwill because they are part of the future development and growth of the business. Goodwill of $45.5 million recognized in connection with the acquisition is not deductible for tax purposes. The Company recognized $7.5 million and $8.9 million of acquisition-related costs, including legal, accounting, compensation arrangements and other related fees that were expensed when incurred in the three and six months ended June 30, 2020, respectively. These costs are recorded in general and administrative expenses in the condensed consolidated statements of operations. Progenics Pro Forma Financial Information Progenics has been included in the Company’s consolidated financial statements since the Closing Date. Progenics contributed revenues of $1.0 million and a net loss of $3.2 million to the Company’s condensed consolidated statement of operations for the three and six months ended June 30, 2020. The following unaudited pro forma financial information presents the Company’s results as if the Progenics Acquisition had occurred on January 1, 2019: Six Months Ended (in thousands) Amount Pro forma revenue $ 167,619 Pro forma net loss 18,115 The unaudited pro forma financial information for all periods presented adjusts for the effects of material business combination items, including amortization of acquired intangible assets, transaction-related costs, adjustments to interest expense related to the assumption of long-term debt, retention and severance bonuses and the corresponding income tax effects of each. These pro forma results have been prepared for comparative purposes only and do not purport to be indicative of the operating results of the Company that would have been achieved had the Progenics Acquisition actually taken place on January 1, 2019. In addition, these results are not intended to be a projection of future results and do not reflect events that may occur after the Progenics Acquisition, including, but not limited to, revenue enhancements, cost savings or operating synergies that the combined company may achieve as a result of the Progenics Acquisition.

Sale of Puerto Rico Subsidiary

Sale of Puerto Rico Subsidiary	6 Months Ended
	Jun. 30, 2021
Discontinued Operations and Disposal Groups [Abstract]
Sale of Puerto Rico Subsidiary	Sale of Puerto Rico Subsidiary During the fourth quarter of 2020, the Company entered into a stock purchase agreement (the “SPA”) with one of its existing radiopharmacy customers to sell all the stock of its Puerto Rico radiopharmacy subsidiary. The assets were classified as held for sale and the Company determined that the fair value of the net assets being sold significantly exceeded the carrying value as of December 31, 2020. The transaction was consummated on January 29, 2021. The purchase price for the stock sale was $18.0 million in cash, which includes a holdback amount of $1.8 million to be due to the Company in January 2022 and will also include a working capital adjustment once settled. The SPA contains customary representations, warranties and covenants by each of the parties. Subject to certain limitations, the buyer will be indemnified for damages resulting from breaches or inaccuracies of the Company’s representations, warranties and covenants in the SPA. As part of the transaction, the Company and the buyer also entered into a customary transition services agreement and a long-term supply contract under which the Company will supply the buyer with certain of the Company’s products on commercial terms and under which the buyer has agreed to certain product minimum purchase commitments. The Company does not believe this sale of certain net assets, reported as held for sale in the international segment prior to the change in segments in the first quarter of 2021, constituted a strategic shift that would have a major effect on its operations or financial results. As a result, this transaction is not classified as discontinued operations in the Company’s accompanying consolidated financial statements. The following table summarizes the major classes of assets and liabilities sold as of January 29, 2021 (date of sale) and held for sale as of December 31, 2020: (in thousands) January 29, 2021 December 31, 2020 Current Assets: Cash and cash equivalents $ 540 $ 941 Accounts receivable, net 1,959 2,191 Inventory 530 420 Other current assets 65 43 Total current assets 3,094 3,595 Non-Current Assets: Property, plant & equipment, net 780 761 Intangibles, net 96 96 Other long-term assets 774 790 Total assets held for sale $ 4,744 $ 5,242 Current Liabilities: Accounts payable $ 185 $ 224 Accrued expense and other liabilities 369 661 Total current liabilities 554 885 Non-Current Liabilities: Asset retirement obligations 306 302 Other long-term liabilities 588 606 Total liabilities held for sale $ 1,448 $ 1,793 The sale resulted in a pre-tax book gain of $15.3 million, which was recorded within operating income in the condensed consolidated statement of operations for the six months ended June 30, 2021.

Asset Retirement Obligations

Asset Retirement Obligations	6 Months Ended
	Jun. 30, 2021
Asset Retirement Obligation Disclosure [Abstract]
Asset Retirement Obligations	Asset Retirement Obligations The Company considers its legal obligation to remediate its facilities upon a decommissioning of its radioactive-related operations as an asset retirement obligation. The Company has production facilities which manufacture and process radioactive materials at its North Billerica, Massachusetts site. As of June 30, 2021, the liability is measured at the present value of the obligation expected to be incurred, of approximately $26.4 million. The Company previously operated a production facility which manufactured and processed radioactive materials at its San Juan, Puerto Rico site. As of December 31, 2020, the liability for the San Juan, Puerto Rico site was recorded in liabilities held for sale and the sale was consummated on January 29, 2021. The following table provides a summary of the changes in the Company’s asset retirement obligations: (in thousands) Amount Balance at January 1, 2021 $ 14,020 Accretion expense 777 Balance at June 30, 2021 $ 14,797 The Company is required to provide the U.S. Nuclear Regulatory Commission and Massachusetts Department of Public Health financial assurance demonstrating the Company’s ability to fund the decommissioning of its North Billerica, Massachusetts production facility upon closure, although the Company does not intend to close the facility. The Company has provided this financial assurance in the form of a $28.2 million surety bond.

Intangibles, Net

Intangibles, Net	6 Months Ended
	Jun. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Intangibles, Net	Intangibles, NetIntangibles, net, consisted of the following: June 30, 2021 (in thousands) Amortization Method Cost Accumulated Amortization Net Trademarks Straight-Line $ 13,540 $ (11,234) $ 2,306 Customer relationships Accelerated 97,022 (94,346) 2,676 Currently marketed products Straight-Line 275,700 (11,205) 264,495 Licenses Straight-Line 85,800 (7,781) 78,019 Developed technology Straight-Line 2,400 (277) 2,123 IPR&D N/A 15,640 — 15,640 Total $ 490,102 $ (124,843) $ 365,259 December 31, 2020 (in thousands) Amortization Method Cost Accumulated Amortization Net Trademarks Straight-Line $ 13,540 $ (10,958) $ 2,582 Customer relationships Accelerated 96,865 (93,770) 3,095 Currently marketed product Straight-Line 142,900 (5,053) 137,847 Licenses Straight-Line 85,800 (4,008) 81,792 Developed technology Straight-Line 2,400 (144) 2,256 IPR&D N/A 148,440 — 148,440 Total $ 489,945 $ (113,933) $ 376,012 The Company recorded amortization expense for its intangible assets of $6.1 million and $0.9 million for the three months ended June 30, 2021 and 2020, respectively, and $10.8 million and $1.3 million for the six months ended June 30, 2021 and 2020, respectively. In May 2021, PyL (18F-DCFPyL) was approved by the FDA under the name PYLARIFY. Accordingly, the Company reclassified the associated asset of $132.8 million from IPR&D to currently marketed products and commenced amortization of the asset. The below table summarizes the estimated aggregate amortization expense expected to be recognized on the above intangible assets: (in thousands) Amount Remainder of 2021 $ 16,746 2022 33,233 2023 32,634 2024 32,563 2025 32,508 2026 and thereafter 201,935 Total $ 349,619

Long-Term Debt, Net, and Other

Long-Term Debt, Net, and Other Borrowings	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
Long-Term Debt, Net, and Other Borrowings	Long-Term Debt, Net, and Other Borrowings As of June 30, 2021, the Company’s maturities of principal obligations under its long-term debt and other borrowings are as follows: (in thousands) Amount Remainder of 2021 $ 5,000 2022 11,250 2023 15,000 2024 148,750 Total principal outstanding 180,000 Unamortized debt discount (598) Unamortized debt issuance costs (516) Finance lease liabilities 735 Total 179,621 Less: current portion (10,372) Total long-term debt, net and other borrowings $ 169,249 At June 30, 2021, the Company’s interest rate under the five-year secured term loan facility, which matures on June 30, 2024 (the “2019 Term Facility”) was 2.4%. On March 31, 2021, the Company voluntarily repaid in full the entire outstanding principal on the original $50.0 million loan agreement (the “Royalty-Backed Loan”) with a fund managed by HealthCare Royalty Partners III, L.P. in the amount of $30.9 million, which included a prepayment amount of $0.5 million, and terminated the agreement governing the Royalty-Backed Loan. The Company recorded a gain on extinguishment of debt of $0.9 million related to the write-off of an unamortized debt premium offset by the prepayment amount.

Derivative Instruments

Derivative Instruments	6 Months Ended
	Jun. 30, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments	Derivative Instruments The Company uses interest rate swaps to reduce the variability in cash flows associated with a portion of the Company’s forecasted interest payments on its variable rate debt. In March 2020, the Company entered into interest rate swap contracts to fix the LIBOR rate on a notional amount of $100.0 million through May 31, 2024. The average fixed LIBOR rate on the interest rate swaps is approximately 0.82%. This agreement involves the receipt of floating rate amounts in exchange for fixed rate interest payments over the life of the agreement without an exchange of the underlying principal amount. The interest rate swaps were designated as cash flow hedges. In accordance with hedge accounting, the interest rate swaps are recorded on the Company’s condensed consolidated balance sheets at fair value, and changes in the fair value of the swap agreements are recorded to other comprehensive loss and reclassified to interest expense in the period during which the hedged transaction affected earnings or it will become probable that the forecasted transaction would not occur. At June 30, 2021, accumulated other comprehensive loss included $0.7 million of pre-tax deferred losses that are expected to be reclassified to earnings during the next 12 months. The following table presents the location and fair value amounts of derivative instruments reported in the condensed consolidated balance sheet: (in thousands) June 30, 2021 December 31, 2020 Derivatives type Classification Liabilities: Interest rate swap Accrued expenses and other liabilities $ 897 $ 1,908

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss	6 Months Ended
	Jun. 30, 2021
Equity [Abstract]
Accumulated Other Comprehensive Loss	Accumulated Other Comprehensive LossThe components of accumulated other comprehensive loss, net of tax of $0.2 million and $0.5 million for the six months ended June 30, 2021 and 2020, respectively, consisted of the following: (in thousands) Foreign currency translation Unrealized loss on cash flow hedges Accumulated other comprehensive loss Balance at January 1, 2021 $ (630) $ (1,418) $ (2,048) Other comprehensive income before reclassifications 296 399 695 Amounts reclassified to earnings — 353 353 Balance at June 30, 2021 $ (334) $ (666) $ (1,000) Balance at January 1, 2020 $ (960) $ — $ (960) Other comprehensive loss before reclassifications (194) (1,528) (1,722) Amounts reclassified to earnings — 76 76 Balance at June 30, 2020 $ (1,154) $ (1,452) $ (2,606)

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2021
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based Compensation The following table presents stock-based compensation expense recognized in the Company’s accompanying condensed consolidated statements of operations: Three Months Ended Six Months Ended (in thousands) 2021 2020 2021 2020 Cost of goods sold $ 906 $ 645 $ 1,528 $ 1,263 Sales and marketing 692 394 1,042 647 General and administrative 2,391 1,994 4,311 3,809 Research and development 599 352 1,024 741 Total stock-based compensation expense $ 4,588 $ 3,385 $ 7,905 $ 6,460

Net (Loss) Income Per Common Sh

Net (Loss) Income Per Common Share	6 Months Ended
	Jun. 30, 2021
Earnings Per Share [Abstract]
Net (Loss) Income Per Common Share	Net (Loss) Income Per Common Share A summary of net (loss) income per common share is presented below: Three Months Ended Six Months Ended (in thousands, except per share amounts) 2021 2020 2021 2020 Net loss $ (26,657) $ (7,012) $ (17,649) $ (3,675) Basic weighted-average common shares outstanding 67,505 43,135 67,300 41,284 Effect of dilutive stock options — — — — Effect of dilutive restricted stock — — — — Diluted weighted-average common shares outstanding 67,505 43,135 67,300 41,284 Basic loss per common share $ (0.39) $ (0.16) $ (0.26) $ (0.09) Diluted loss per common share $ (0.39) $ (0.16) $ (0.26) $ (0.09) Antidilutive securities excluded from diluted net income per common share 3,173 1,649 3,173 1,517

Other Income

Other Income	6 Months Ended
	Jun. 30, 2021
Other Income and Expenses [Abstract]
Other Income	Other Income Other income consisted of the following: Three Months Ended Six Months Ended (in thousands) 2021 2020 2021 2020 Foreign currency (gains) losses $ (13) $ (94) $ 29 $ 220 Tax indemnification income, net (158) (554) (731) (1,109) Interest income (11) (105) (28) (214) Other — (3) (1) (3) Total other income $ (182) $ (756) $ (731) $ (1,106)

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Legal Proceedings From time to time, the Company is a party to various legal proceedings arising in the ordinary course of business. In addition, the Company has in the past been, and may in the future be, subject to investigations by governmental and regulatory authorities, which expose it to greater risks associated with litigation, regulatory or other proceedings, as a result of which the Company could be required to pay significant fines or penalties. The costs and outcome of litigation, regulatory or other proceedings cannot be predicted with certainty, and some lawsuits, claims, actions or proceedings may be disposed of unfavorably to the Company and could have a material adverse effect on the Company’s results of operations or financial condition. In addition, intellectual property disputes often have a risk of injunctive relief which, if imposed against the Company, could materially and adversely affect its financial condition or results of operations. If a matter is both probable to result in material liability and the amount of loss can be reasonably estimated, the Company estimates and discloses the possible material loss or range of loss. If such loss is not probable or cannot be reasonably estimated, a liability is not recorded in its condensed consolidated financial statements. As of June 30, 2021, the Company had the following material ongoing litigation in which the Company was a party: RELISTOR European Opposition Proceedings In October 2015, Progenics received notices of opposition to three European patents relating to methylnaltrexone: EP1615646, EP2368553 and EP2368554. Notices of opposition were filed separately by each of Actavis Group PTC ehf and Fresenius Kabi Deutschland GmbH. Between May 11, 2017 and July 4, 2017, the opposition division provided notice that the three European patents would be revoked. Each of these matters were appealed to with the European Patent Office. On November 13, 2020, Progenics withdrew the appeal for EP2368553 and EP2368554. Notices of termination of the proceedings with revocation of the patent were issued on November 23, 2020 for both patents. Oral proceedings for the third patent, EP1615646 were held on September 22, 2020. The decision under appeal was set aside and the case was remitted to the opposition division for further prosecution. The deadline for written submissions prior to an oral hearing is July 27, 2021. The oral hearing is set for September 27, 2021. Because the outcome of litigation is uncertain, the Company cannot predict how or when this matter will ultimately be resolved. German PSMA-617 Litigation On November 8, 2018, Molecular Insight Pharmaceuticals, Inc., a subsidiary of Progenics (“MIP”), filed a complaint against the University of Heidelberg (the “University”) in the District Court in Mannheim, Germany (the “German District Court”). In this Complaint, MIP claimed that the discovery and development of PSMA-617 was related to work performed under a research collaboration sponsored by MIP. MIP alleged that the University breached certain contracts with MIP and that MIP is the co-owner of inventions embodied in certain worldwide patent filings related to PSMA-617 that were filed by the University. On February 27, 2019, Endocyte, Inc., a wholly owned subsidiary of Novartis AG, filed a motion to intervene in the German litigation. Endocyte is the exclusive licensee of the patent rights that are the subject of the German proceedings. On November 27, 2018, MIP requested that the European Patent Office (“EPO”) stay the examination of a certain European Patent and related Divisional Applications, pending a decision from the German District Court on MIP’s Complaint. On December 10, 2018, the EPO granted MIP’s request and stayed the examination of the patent and patent applications effective November 27, 2018. MIP filed a Confirmation of Ownership with the United States Patent and Trademark Office (“USPTO”) in corresponding U.S. patent applications (U.S. Serial Nos. 15/131,118; 15/805,900; 16/038,729, 16/114,988, 16/510,495, 16/551,198, and 17/110,558). MIP’s filing with the USPTO takes the position that, in light of the collaboration and contracts between MIP and the University, MIP is the co-owner of these pending U.S. patent applications (U.S. Serial Nos. 16/510,495, 16/551,198). On March 6, 2020, MIP filed with the USPTO a notice stating that the Power of Attorney in certain pending U.S. patent applications was signed by less than all applicants or owners of the applications. On February 27, 2019, the German District Court set €0.4 million as the amount MIP must deposit with the German District Court as security in the event of an unfavorable final decision on the merits of the dispute. The German District Court held the first oral hearing in the case on August 6, 2019. The German District Court considered procedural matters and granted the parties the right to make further submissions. A further oral hearing occurred July 23, 2020, during which the German District Court heard live testimony from several witnesses, testifying on behalf of the defendants. On August 24, 2020, the German District Court issued its decision dismissing MIP’s claims, stating that MIP failed to discharge its burden of proof in the matter. MIP filed a Notice of Appeal of the German District Court’s decision on September 24, 2020 and filed its appeal brief on November 26, 2020. The University and Endocyte each filed oppositions to MIP’s Notice of Appeal on March 12, 2021. MIP is also considering its legal and procedural alternatives against the defendants in other jurisdictions and proceedings. If MIP is not successful in its appeal, it will be responsible for the German court fees and fees and disbursements of defendant’s and intervenor’s counsel, both at first instance and on appeal. Most of such fees and disbursements at first instance are covered by a cash security deposited with the German District Court. Because the outcome of litigation is uncertain, the Company cannot predict how or when this matter will ultimately be resolved. Petition for Post-Grant Review On February 4, 2021, Advanced Accelerator Applications USA, Inc. (“AAA”) filed a petition for post-grant review of U.S. Patent No. 10,640,461 (the “’461 patent”) with the Patent Trial and Appeal Board (“PTAB”) of the United States Patent and Trademark Office. The ’461 patent is owned by MIP. In the petition, AAA challenges the patentability of claims 1, 45, and 47 of the ’461 patent under 35 U.S.C. §§ 112 and 102(a)(1). On February 9, 2021, the PTAB mailed a Notice of Filing Date Accorded to Petition and Time for Filing Patent Owner Preliminary Response. The PTAB set a three month deadline for MIP to file a preliminary response. The filing of a preliminary response to the petition is optional for MIP as the patent owner. Should the PTAB decide to institute post-grant review, a schedule will be set, and MIP will be afforded three months from the date of institution to formally respond to the petition. Because the outcome of litigation is uncertain, the Company cannot predict how or when this matter will be ultimately resolved.

Segment Information

Segment Information	6 Months Ended
	Jun. 30, 2021
Segment Reporting [Abstract]
Segment Information	Segment InformationIn the first quarter of fiscal year 2021, the Company completed the evaluation of its operating and reporting structure, including the impact on the Company’s business of the acquisition of Progenics described in Notes 1 and 8, and the sale of the Puerto Rico subsidiary in the first quarter, which resulted in a change in operating and reportable segments. The Company now operates as one business segment: the development, manufacture and sale of innovative diagnostic and therapeutic agents and products that assist clinicians in the diagnosis and treatment of heart disease, cancer and other diseases. This conclusion reflects the Company’s focus on the performance of the business on a consolidated worldwide basis. The results of this operating segment are regularly reviewed by the Company’s chief operating decision maker, the President and Chief Executive Officer. The Company’s chief operating decision maker does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company’s consolidated operating results.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2021
Subsequent Events [Abstract]
Subsequent Events	Subsequent EventsIn the third quarter of 2021, the Company concluded its assessment of eligibility related to first quarter 2021 qualified wages for the Coronavirus Aid, Relief and Economic Security Act Employee Retention Credit (“ERTC”). The Company plans to file an amended tax return for the first quarter of 2021 to claim the ERTC and continues to evaluate eligibility as related to the second quarter 2021 qualified wages.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation	The accompanying unaudited condensed consolidated financial statements include the accounts of Holdings and its direct and indirect wholly-owned subsidiaries, including Progenics (as of the Closing Date, as defined below), and have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these condensed consolidated financial statements do not include all of the information and notes required by generally accepted accounting principles in the United States of America (“U.S. GAAP”) for complete financial statements. In the opinion of management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement have been included. The results of operations for the three and six months ended June 30, 2021 are not necessarily indicative of the results that may be expected for the year ended December 31, 2021 or any future period. In the first quarter of fiscal year 2021, the Company completed the evaluation of its operating and reporting structure, which resulted in a change in operating segments. Please refer to Note 19, “Segment Information”, for further details. The condensed consolidated balance sheet at December 31, 2020 has been derived from the audited consolidated financial statements at that date but does not include all the information and notes required by U.S. GAAP for complete financial statements. These condensed consolidated financial statements and accompanying notes should be read in conjunction with the consolidated financial statements and notes thereto included in Item 8 of the Company’s most recent Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities Exchange Commission (“SEC”) on February 25, 2021.
Reclassifications	Reclassifications Certain immaterial reclassifications in the prior period consolidated statement of cash flows have been reclassified to conform to the current year period financial statement presentation. Reclassifications include $0.2 million from provision for bad debt to other at June 30, 2020. The Company had a reclassification in presentation related to rebates and allowances within product revenue. Please refer to Note 3, “Revenue from Contracts with Customers” for further details.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Standard Description Effect on the Condensed Consolidated Financial Statements Accounting Standards Adopted During the Six Months Ended June 30, 2021 ASU 2020-06, “Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40)” This ASU provides guidance to simplify the complexity associated with accounting for convertible instruments and derivatives. For convertible instruments, the number of major separation models required were reduced. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. This ASU further amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. The ASU simplifies the diluted net income per share calculation in certain areas as well. January 1, 2021 The adoption of this standard did not have a material impact on the Company’s condensed consolidated financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Recent Accounting Pronouncements	Standard Description Effect on the Condensed Consolidated Financial Statements Accounting Standards Adopted During the Six Months Ended June 30, 2021 ASU 2020-06, “Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40)” This ASU provides guidance to simplify the complexity associated with accounting for convertible instruments and derivatives. For convertible instruments, the number of major separation models required were reduced. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. This ASU further amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. The ASU simplifies the diluted net income per share calculation in certain areas as well. January 1, 2021 The adoption of this standard did not have a material impact on the Company’s condensed consolidated financial statements.

Revenue from Contracts with C_2

Revenue from Contracts with Customers (Tables)	6 Months Ended
	Jun. 30, 2021
Revenue from Contract with Customer [Abstract]
Schedule of disaggregation of revenue	The following table summarizes revenue by revenue source as follows: Three Months Ended Six Months Ended Major Products/Service Lines (in thousands) 2021 2020 2021 2020 Product revenue, net (1) $ 93,562 $ 64,927 $ 180,881 $ 155,140 License and royalty revenues 7,502 1,083 12,692 1,574 Total revenues $ 101,064 $ 66,010 $ 193,573 $ 156,714 ________________________________ (1) The Company’s principal products include DEFINITY and TechneLite and are categorized within product revenue, net. The Company applies the same revenue recognition policies and judgments for all its principal products. The Company classifies its revenues into three product categories: precision diagnostics, radiopharmaceutical oncology, and strategic partnerships and other. Precision diagnostics includes DEFINITY, TechneLite and other imaging diagnostic products. Radiopharmaceutical oncology consists primarily of AZEDRA and PYLARIFY. Strategic partnerships and other includes partnerships related to other products, such as RELISTOR, that improve patient outcomes and care. Revenue by product category on a net basis is as follows: Three Months Ended Six Months Ended (in thousands) 2021 2020 (1) 2021 2020 (1) DEFINITY $ 59,842 $ 37,125 $ 115,813 $ 89,630 TechneLite 23,772 18,668 46,572 41,447 Other precision diagnostics 6,742 7,140 13,726 20,197 Total precision diagnostics 90,356 62,933 176,111 151,274 Radiopharmaceutical oncology 2,812 2,183 4,312 4,151 Strategic partnerships and other 7,896 894 13,150 1,289 Total revenues $ 101,064 $ 66,010 $ 193,573 $ 156,714 ________________________________ (1) The Company reclassified rebates and allowances of $3.5 million and $8.2 million within each product category, which included $3.2 million and $7.5 million for DEFINITY, $0.3 million and $0.6 million for TechneLite and zero and $0.1 million for other precision diagnostics, for the three and six months ended June 30, 2020, respectively.

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2021
Fair Value Disclosures [Abstract]
Schedule of assets and liabilities measured at fair value on a recurring basis	The tables below present information about the Company’s assets and liabilities measured at fair value on a recurring basis: June 30, 2021 (in thousands) Total Fair Level 1 Level 2 Level 3 Assets: Money market $ 38,547 $ 38,547 $ — $ — Contingent receivable 13,400 — — 13,400 Total assets $ 51,947 $ 38,547 $ — $ 13,400 Liabilities: Interest rate swaps $ 897 $ — $ 897 $ — Contingent consideration liabilities 43,800 — — 43,800 Total liabilities $ 44,697 $ — $ 897 $ 43,800 December 31, 2020 (in thousands) Total Fair Level 1 Level 2 Level 3 Assets: Money market $ 35,457 $ 35,457 $ — $ — Contingent receivable 11,300 — — 11,300 Total assets $ 46,757 $ 35,457 $ — $ 11,300 Liabilities: Interest rate swaps $ 1,908 $ — $ 1,908 $ — Contingent consideration liabilities 15,800 — — 15,800 Total liabilities $ 17,708 $ — $ 1,908 $ 15,800
Fair Value Measurement Inputs and Valuation Techniques	The following tables summarize quantitative information and assumptions pertaining to the fair value measurement of assets and liabilities using Level 3 inputs at June 30, 2021. Fair Value at Assumptions (in thousands) June 30, 2021 December 31, 2020 Valuation Technique Unobservable Input June 30, 2021 December 31, 2020 Contingent receivable: Regulatory milestone $ 3,300 $ 3,200 Probability adjusted discounted cash flow model Period of expected milestone achievement 2022 2021 Probability of success 90 % 90 % Discount rate 18 % 24 % Royalties 10,100 8,100 Probability adjusted discounted cash flow model Probability of success 13% - 77% 13% - 77% Discount rate 18 % 24 % Total $ 13,400 $ 11,300 Fair Value at Assumptions (in thousands) June 30, 2021 December 31, 2020 Valuation Technique Unobservable Input June 30, 2021 December 31, 2020 Contingent consideration liability: Net sales targets - PYLARIFY (CVRs) $ 30,400 $ 4,200 Monte-Carlo simulation Period of expected milestone achievement 2022 - 2023 2022 - 2023 Discount rate 18 % 24 % 1095 commercialization milestone 1,900 2,200 Probability adjusted discounted cash flow model Period of expected milestone achievement 2026 2026 Probability of success 40 % 45 % Discount rate 0.9 % 0.5 % Net sales targets - AZEDRA and 1095 11,500 9,400 Monte-Carlo simulation Probability of success 40% - 100% 40% - 100% Discount rate 17% - 18% 23% - 24% Total $ 43,800 $ 15,800
Schedule of financial instruments with significant Level 3 inputs	For those financial instruments with significant Level 3 inputs, the following table summarizes the activities for the periods indicated: Financial Assets Financial Liabilities (in thousands) Six Months Ended Six Months Ended 2021 2020 2021 2020 Fair value, beginning of period $ 11,300 $ — $ 15,800 $ — Progenics acquisition — 10,100 — 16,300 Changes in fair value included in net loss 2,100 — 28,000 — Fair value, end of period $ 13,400 $ 10,100 $ 43,800 $ 16,300

Income Taxes (Tables)

Income Taxes (Tables)	6 Months Ended
	Jun. 30, 2021
Income Tax Disclosure [Abstract]
Schedule of income tax expense	The Company’s income tax expense is presented below: Three Months Ended Six Months Ended (in thousands) 2021 2020 2021 2020 Income tax (benefit) expense $ (1,879) $ 309 $ 3,455 $ 2,501

Inventory (Tables)

Inventory (Tables)	6 Months Ended
	Jun. 30, 2021
Inventory Disclosure [Abstract]
Schedule of inventory	Inventory consisted of the following: (in thousands) June 30, December 31, Raw materials $ 14,578 $ 16,000 Work in process 11,687 11,212 Finished goods 5,454 8,532 Total inventory $ 31,719 $ 35,744

Property, Plant and Equipment_2

Property, Plant and Equipment, Net (Tables)	6 Months Ended
	Jun. 30, 2021
Property, Plant and Equipment [Abstract]
Schedule of property, plant, and equipment, net	Property, plant and equipment, net, consisted of the following: (in thousands) June 30, December 31, Land $ 13,450 $ 13,450 Buildings 72,472 70,381 Machinery, equipment and fixtures 83,758 77,854 Computer software 24,110 23,644 Construction in progress 7,431 11,254 201,221 196,583 Less: accumulated depreciation and amortization (82,728) (76,412) Total property, plant and equipment, net $ 118,493 $ 120,171

Business Combinations (Tables)

Business Combinations (Tables)	6 Months Ended
	Jun. 30, 2021
Business Combination and Asset Acquisition [Abstract]
Schedule of business acquisition	The acquisition date fair value of the consideration transferred in the acquisition consisted of the following: (in thousands) Amount Issuance of common stock $ 398,110 Fair value of replacement options 7,125 Fair value of bridge loan settled at close 10,074 Fair value of contingent considerations (CVRs) 3,700 Total consideration transferred (1) $ 419,009 (1) Non-cash investing and financing activities in the condensed consolidated statements of cash flows
Schedule of fair value disclosure of asset and liability	The following table summarizes the provisional amounts recognized for assets acquired and liabilities assumed as of the acquisition date, as well as measurement period adjustments made to the amounts initially recorded in June 2020. The measurement period adjustments primarily resulted from finalizing the fair values of certain intangible assets and liabilities, deferred taxes and other changes to certain tangible assets and liability accounts. Measurement period adjustments were recognized in the reporting period in which the adjustments were determined and calculated as if the accounting had been completed at the acquisition date. The related impact to net loss that would have been recognized in previous periods if the adjustments were recognized as of the acquisition date is immaterial to the consolidated financial statements. (in thousands) Amounts Recognized as of Acquisition Date Measurement Period Adjustments Amounts Recognized as of Acquisition Date Cash and cash equivalents $ 15,421 $ — $ 15,421 Accounts receivable 5,787 — 5,787 Inventory 915 160 1,075 Other current assets 3,250 434 3,684 Property, plant and equipment 14,972 — 14,972 Identifiable intangible assets (weighted average useful life): Currently marketed product (15 years) 142,100 800 142,900 Licenses (11.5 years) 87,500 (1,700) 85,800 Developed technology (9 years) 3,000 (600) 2,400 IPR&D 150,900 200 151,100 Other long-term assets 37,631 — 37,631 Accounts payable (1,616) — (1,616) Accrued expenses and other liabilities (8,207) (80) (8,287) Other long-term liabilities (30,778) (380) (31,158) Long-term debt and other borrowings (40,200) — (40,200) Deferred tax liabilities (3,717) (2,258) (5,975) Goodwill 42,051 3,424 45,475 Total consideration transferred $ 419,009 $ — $ 419,009
Schedule pro forma financial information	The following unaudited pro forma financial information presents the Company’s results as if the Progenics Acquisition had occurred on January 1, 2019: Six Months Ended (in thousands) Amount Pro forma revenue $ 167,619 Pro forma net loss 18,115

Sale of Puerto Rico Subsidiary

Sale of Puerto Rico Subsidiary (Tables)	6 Months Ended
	Jun. 30, 2021
Discontinued Operations and Disposal Groups [Abstract]
Disposal groups including discontinued operations	The following table summarizes the major classes of assets and liabilities sold as of January 29, 2021 (date of sale) and held for sale as of December 31, 2020: (in thousands) January 29, 2021 December 31, 2020 Current Assets: Cash and cash equivalents $ 540 $ 941 Accounts receivable, net 1,959 2,191 Inventory 530 420 Other current assets 65 43 Total current assets 3,094 3,595 Non-Current Assets: Property, plant & equipment, net 780 761 Intangibles, net 96 96 Other long-term assets 774 790 Total assets held for sale $ 4,744 $ 5,242 Current Liabilities: Accounts payable $ 185 $ 224 Accrued expense and other liabilities 369 661 Total current liabilities 554 885 Non-Current Liabilities: Asset retirement obligations 306 302 Other long-term liabilities 588 606 Total liabilities held for sale $ 1,448 $ 1,793

Asset Retirement Obligations (T

Asset Retirement Obligations (Tables)	6 Months Ended
	Jun. 30, 2021
Asset Retirement Obligation Disclosure [Abstract]
Summary of changes in asset retirement obligations	The following table provides a summary of the changes in the Company’s asset retirement obligations: (in thousands) Amount Balance at January 1, 2021 $ 14,020 Accretion expense 777 Balance at June 30, 2021 $ 14,797

Intangibles, Net (Tables)

Intangibles, Net (Tables)	6 Months Ended
	Jun. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of intangibles	Intangibles, net, consisted of the following: June 30, 2021 (in thousands) Amortization Method Cost Accumulated Amortization Net Trademarks Straight-Line $ 13,540 $ (11,234) $ 2,306 Customer relationships Accelerated 97,022 (94,346) 2,676 Currently marketed products Straight-Line 275,700 (11,205) 264,495 Licenses Straight-Line 85,800 (7,781) 78,019 Developed technology Straight-Line 2,400 (277) 2,123 IPR&D N/A 15,640 — 15,640 Total $ 490,102 $ (124,843) $ 365,259 December 31, 2020 (in thousands) Amortization Method Cost Accumulated Amortization Net Trademarks Straight-Line $ 13,540 $ (10,958) $ 2,582 Customer relationships Accelerated 96,865 (93,770) 3,095 Currently marketed product Straight-Line 142,900 (5,053) 137,847 Licenses Straight-Line 85,800 (4,008) 81,792 Developed technology Straight-Line 2,400 (144) 2,256 IPR&D N/A 148,440 — 148,440 Total $ 489,945 $ (113,933) $ 376,012
Schedule of intangibles	Intangibles, net, consisted of the following: June 30, 2021 (in thousands) Amortization Method Cost Accumulated Amortization Net Trademarks Straight-Line $ 13,540 $ (11,234) $ 2,306 Customer relationships Accelerated 97,022 (94,346) 2,676 Currently marketed products Straight-Line 275,700 (11,205) 264,495 Licenses Straight-Line 85,800 (7,781) 78,019 Developed technology Straight-Line 2,400 (277) 2,123 IPR&D N/A 15,640 — 15,640 Total $ 490,102 $ (124,843) $ 365,259 December 31, 2020 (in thousands) Amortization Method Cost Accumulated Amortization Net Trademarks Straight-Line $ 13,540 $ (10,958) $ 2,582 Customer relationships Accelerated 96,865 (93,770) 3,095 Currently marketed product Straight-Line 142,900 (5,053) 137,847 Licenses Straight-Line 85,800 (4,008) 81,792 Developed technology Straight-Line 2,400 (144) 2,256 IPR&D N/A 148,440 — 148,440 Total $ 489,945 $ (113,933) $ 376,012
Schedule of expected future amortization expense	The below table summarizes the estimated aggregate amortization expense expected to be recognized on the above intangible assets: (in thousands) Amount Remainder of 2021 $ 16,746 2022 33,233 2023 32,634 2024 32,563 2025 32,508 2026 and thereafter 201,935 Total $ 349,619

Long-Term Debt, Net, and Othe_2

Long-Term Debt, Net, and Other Borrowings (Tables)	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
Schedule of maturities of principal obligations	As of June 30, 2021, the Company’s maturities of principal obligations under its long-term debt and other borrowings are as follows: (in thousands) Amount Remainder of 2021 $ 5,000 2022 11,250 2023 15,000 2024 148,750 Total principal outstanding 180,000 Unamortized debt discount (598) Unamortized debt issuance costs (516) Finance lease liabilities 735 Total 179,621 Less: current portion (10,372) Total long-term debt, net and other borrowings $ 169,249

Derivative Instruments (Tables)

Derivative Instruments (Tables)	6 Months Ended
	Jun. 30, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of derivative instruments	The following table presents the location and fair value amounts of derivative instruments reported in the condensed consolidated balance sheet: (in thousands) June 30, 2021 December 31, 2020 Derivatives type Classification Liabilities: Interest rate swap Accrued expenses and other liabilities $ 897 $ 1,908

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Loss (Tables)	6 Months Ended
	Jun. 30, 2021
Equity [Abstract]
Schedule of accumulated other comprehensive income	The components of accumulated other comprehensive loss, net of tax of $0.2 million and $0.5 million for the six months ended June 30, 2021 and 2020, respectively, consisted of the following: (in thousands) Foreign currency translation Unrealized loss on cash flow hedges Accumulated other comprehensive loss Balance at January 1, 2021 $ (630) $ (1,418) $ (2,048) Other comprehensive income before reclassifications 296 399 695 Amounts reclassified to earnings — 353 353 Balance at June 30, 2021 $ (334) $ (666) $ (1,000) Balance at January 1, 2020 $ (960) $ — $ (960) Other comprehensive loss before reclassifications (194) (1,528) (1,722) Amounts reclassified to earnings — 76 76 Balance at June 30, 2020 $ (1,154) $ (1,452) $ (2,606)

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2021
Share-based Payment Arrangement [Abstract]
Schedule of stock-based compensation expense recognized	The following table presents stock-based compensation expense recognized in the Company’s accompanying condensed consolidated statements of operations: Three Months Ended Six Months Ended (in thousands) 2021 2020 2021 2020 Cost of goods sold $ 906 $ 645 $ 1,528 $ 1,263 Sales and marketing 692 394 1,042 647 General and administrative 2,391 1,994 4,311 3,809 Research and development 599 352 1,024 741 Total stock-based compensation expense $ 4,588 $ 3,385 $ 7,905 $ 6,460

Net (Loss) Income Per Common _2

Net (Loss) Income Per Common Share (Tables)	6 Months Ended
	Jun. 30, 2021
Earnings Per Share [Abstract]
Summary of net (loss) income per common share	A summary of net (loss) income per common share is presented below: Three Months Ended Six Months Ended (in thousands, except per share amounts) 2021 2020 2021 2020 Net loss $ (26,657) $ (7,012) $ (17,649) $ (3,675) Basic weighted-average common shares outstanding 67,505 43,135 67,300 41,284 Effect of dilutive stock options — — — — Effect of dilutive restricted stock — — — — Diluted weighted-average common shares outstanding 67,505 43,135 67,300 41,284 Basic loss per common share $ (0.39) $ (0.16) $ (0.26) $ (0.09) Diluted loss per common share $ (0.39) $ (0.16) $ (0.26) $ (0.09) Antidilutive securities excluded from diluted net income per common share 3,173 1,649 3,173 1,517

Other Income (Tables)

Other Income (Tables)	6 Months Ended
	Jun. 30, 2021
Other Income and Expenses [Abstract]
Schedule of other income	Other income consisted of the following: Three Months Ended Six Months Ended (in thousands) 2021 2020 2021 2020 Foreign currency (gains) losses $ (13) $ (94) $ 29 $ 220 Tax indemnification income, net (158) (554) (731) (1,109) Interest income (11) (105) (28) (214) Other — (3) (1) (3) Total other income $ (182) $ (756) $ (731) $ (1,106)

Basis of Presentation (Details)

Basis of Presentation (Details) $ / shares in Units, $ in Thousands	Feb. 20, 2020USD ($)contingent_value_right$ / sharesshares	Jun. 30, 2021USD ($)day$ / shares	Dec. 31, 2020USD ($)$ / shares	Jun. 19, 2020USD ($)
Business Acquisition [Line Items]
Common stock, par value (in dollars per share) | $ / shares		$ 0.01	$ 0.01
Contingent consideration liabilities		$ 43,800	$ 15,800
Business combination, consideration transferred, equity interests issued (in shares) | shares	26,844,877
Business combination common stock under contingent value right (in shares) | shares	86,630,633
Maximum
Business Acquisition [Line Items]
No of working days | day		5
Minimum
Business Acquisition [Line Items]
No of working days | day		4
Progenics
Business Acquisition [Line Items]
Common stock, par value (in dollars per share) | $ / shares	$ 0.0013
Progenics
Business Acquisition [Line Items]
Common stock, par value (in dollars per share) | $ / shares	$ 0.01
Shares to be received from acquisition conversion (in shares) | shares	0.31
Number of CVRs | contingent_value_right	1
Percentage of net sales, contingent consideration	40.00%
Contingent consideration liabilities				$ 3,700
Percentage of total contingent consideration under CVRs	19.90%
Business combination contingent value right of total consideration	$ 100,000
Progenics | Cash Payments 2022
Business Acquisition [Line Items]
Contingent consideration liabilities	100,000
Progenics | Cash Payments 2023
Business Acquisition [Line Items]
Contingent consideration liabilities	$ 150,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Narrative (Details) $ in Millions	3 Months Ended
	Jun. 30, 2020USD ($)
Revision of Prior Period, Reclassification, Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Provision for bad debt	$ (0.2)

Revenue from Contracts with C_3

Revenue from Contracts with Customers (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Disaggregation of Revenue [Line Items]
Revenues	$ 101,064	$ 66,010	$ 193,573	$ 156,714
Reclassification of rebates and allowances		3,500		8,200
Product revenue, net
Disaggregation of Revenue [Line Items]
Revenues	93,562	64,927	180,881	155,140
License and royalty revenues
Disaggregation of Revenue [Line Items]
Revenues	7,502	1,083	12,692	1,574
Total precision diagnostics
Disaggregation of Revenue [Line Items]
Revenues	90,356	62,933	176,111	151,274
DEFINITY
Disaggregation of Revenue [Line Items]
Revenues	59,842	37,125	115,813	89,630
Reclassification of rebates and allowances		3,200		7,500
TechneLite
Disaggregation of Revenue [Line Items]
Revenues	23,772	18,668	46,572	41,447
Reclassification of rebates and allowances		300		600
Other precision diagnostics
Disaggregation of Revenue [Line Items]
Revenues	6,742	7,140	13,726	20,197
Reclassification of rebates and allowances		0		100
Radiopharmaceutical oncology
Disaggregation of Revenue [Line Items]
Revenues	2,812	2,183	4,312	4,151
Strategic partnerships and other
Disaggregation of Revenue [Line Items]
Revenues	$ 7,896	$ 894	$ 13,150	$ 1,289

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Assets and Liabilities Measured at Fair Value on A Recurring Basis (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent receivable	$ 13,400	$ 11,300
Total assets	51,947	46,757
Contingent consideration liabilities	43,800	15,800
Total liabilities	44,697	17,708
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent receivable	0	0
Total assets	38,547	35,457
Contingent consideration liabilities	0	0
Total liabilities	0	0
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent receivable	0	0
Total assets	0	0
Contingent consideration liabilities	0	0
Total liabilities	897	1,908
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent receivable	13,400	11,300
Total assets	13,400	11,300
Contingent consideration liabilities	43,800	15,800
Total liabilities	43,800	15,800
Interest Rate Swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate swaps	897	1,908
Interest Rate Swaps | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate swaps	0	0
Interest Rate Swaps | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate swaps	897	1,908
Interest Rate Swaps | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate swaps	0	0
Money market
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market	38,547	35,457
Money market | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market	38,547	35,457
Money market | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market	0	0
Money market | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market	$ 0	$ 0

Fair Value of Financial Instr_4

Fair Value of Financial Instruments - Narrative (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)
Fair Value, Option, Quantitative Disclosures [Line Items]
Company acquired right to receive certain future milestone	$ 101,064,000	$ 66,010,000	$ 193,573,000	$ 156,714,000
Progenics Pharmaceuticals Inc
Fair Value, Option, Quantitative Disclosures [Line Items]
Royalty percentage			0.05
Potential payments, high	85,000,000		$ 85,000,000
Progenics Pharmaceuticals Inc | Net Sales Targets For Azedra
Fair Value, Option, Quantitative Disclosures [Line Items]
Potential payments, high	70,000,000		70,000,000
Progenics Pharmaceuticals Inc | 1095 commercialization milestone
Fair Value, Option, Quantitative Disclosures [Line Items]
Potential payments, high	5,000,000		5,000,000
Progenics Pharmaceuticals Inc | 1404 Commercialization Milestone
Fair Value, Option, Quantitative Disclosures [Line Items]
Business Combination, Contingent Consideration Arrangements, Range Of Outcomes Not Reasonably Possible, Value	$ 10,000,000		10,000,000
Royalty | Progenics Pharmaceuticals Inc
Fair Value, Option, Quantitative Disclosures [Line Items]
Company acquired right to receive certain future milestone			$ 5,000,000

Fair Value of Financial Instr_5

Fair Value of Financial Instruments - Quantitative Information and Assumptions Pertaining To The Fair Value Measurement of The Level 3 Inputs (Details) $ in Thousands	Jun. 30, 2021USD ($)	Dec. 31, 2020USD ($)
Fair Value, Option, Quantitative Disclosures [Line Items]
Contingent receivable	$ 13,400	$ 11,300
Contingent consideration liabilities	43,800	15,800
Level 3
Fair Value, Option, Quantitative Disclosures [Line Items]
Contingent receivable	13,400	11,300
Contingent consideration liabilities	43,800	15,800
Level 3 | Regulatory milestone
Fair Value, Option, Quantitative Disclosures [Line Items]
Contingent receivable	3,300	3,200
Level 3 | Royalties
Fair Value, Option, Quantitative Disclosures [Line Items]
Contingent receivable	10,100	8,100
Level 3 | CVRs
Fair Value, Option, Quantitative Disclosures [Line Items]
Contingent consideration liabilities	30,400	4,200
Level 3 | 1095 commercialization milestone
Fair Value, Option, Quantitative Disclosures [Line Items]
Contingent consideration liabilities	1,900	2,200
Level 3 | Net sales targets - AZEDRA and 1095
Fair Value, Option, Quantitative Disclosures [Line Items]
Contingent consideration liabilities	$ 11,500	$ 9,400
Level 3 | Probability adjusted discounted cash flow model | Probability of success | Regulatory milestone
Fair Value, Option, Quantitative Disclosures [Line Items]
Asset measurement input	0.90	0.90
Level 3 | Probability adjusted discounted cash flow model | Probability of success | Royalties | Minimum
Fair Value, Option, Quantitative Disclosures [Line Items]
Asset measurement input	0.13	0.13
Level 3 | Probability adjusted discounted cash flow model | Probability of success | Royalties | Maximum
Fair Value, Option, Quantitative Disclosures [Line Items]
Asset measurement input	0.77	0.77
Level 3 | Probability adjusted discounted cash flow model | Probability of success | 1095 commercialization milestone
Fair Value, Option, Quantitative Disclosures [Line Items]
Liability measurement input	0.40	0.45
Level 3 | Probability adjusted discounted cash flow model | Discount rate | Regulatory milestone
Fair Value, Option, Quantitative Disclosures [Line Items]
Asset measurement input	0.18	0.24
Level 3 | Probability adjusted discounted cash flow model | Discount rate | Royalties
Fair Value, Option, Quantitative Disclosures [Line Items]
Asset measurement input	0.18	0.24
Level 3 | Probability adjusted discounted cash flow model | Discount rate | 1095 commercialization milestone
Fair Value, Option, Quantitative Disclosures [Line Items]
Liability measurement input	0.009	0.005
Level 3 | Monte-Carlo simulation | Probability of success | Net sales targets - AZEDRA and 1095 | Minimum
Fair Value, Option, Quantitative Disclosures [Line Items]
Liability measurement input	0.40	0.40
Level 3 | Monte-Carlo simulation | Probability of success | Net sales targets - AZEDRA and 1095 | Maximum
Fair Value, Option, Quantitative Disclosures [Line Items]
Liability measurement input	1	1
Level 3 | Monte-Carlo simulation | Discount rate | CVRs
Fair Value, Option, Quantitative Disclosures [Line Items]
Liability measurement input	0.18	0.24
Level 3 | Monte-Carlo simulation | Discount rate | Net sales targets - AZEDRA and 1095 | Minimum
Fair Value, Option, Quantitative Disclosures [Line Items]
Liability measurement input	0.17	0.23
Level 3 | Monte-Carlo simulation | Discount rate | Net sales targets - AZEDRA and 1095 | Maximum
Fair Value, Option, Quantitative Disclosures [Line Items]
Liability measurement input	0.18	0.24

Fair Value of Financial Instr_6

Fair Value of Financial Instruments - Financial Instruments With Significant Level 3 Inputs (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Financial Assets
Fair value, beginning of period	$ 11,300	$ 0
Progenics acquisition	0	10,100
Changes in fair value included in net loss	2,100	0
Fair value, end of period	13,400	10,100
Financial Liabilities
Fair value, beginning of period	15,800	0
Progenics acquisition	0	16,300
Changes in fair value included in net loss	28,000	0
Fair value, end of period	43,800	$ 16,300
Change in fair value of the contingent financial asset and contingent financial liabilities	$ 25,900

Income Taxes (Detail)

Income Taxes (Detail) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Valuation Allowance [Line Items]
Income tax (benefit) expense	$ (1,879)		$ 309	$ 3,455	$ 2,501
Uncertain tax positions	700			700
Income tax interest and penalties expense	500			500
Unrecognized tax benefits decrease resulting from settlements with taxing authorities	500			500
Unrecognized tax benefits income tax penalties and interest expense settlements with taxing authorities	400			400
Reduction from lapse of statute of limitations	200			200
Goodwill acquired		$ 2,600
UNITED KINGDOM
Valuation Allowance [Line Items]
Deferred tax asset, valuation allowance	1,200			1,200
SWEDEN
Valuation Allowance [Line Items]
Deferred tax asset, valuation allowance	$ 2,200			$ 2,200

Inventory (Details)

Inventory (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Inventory [Line Items]
Raw materials	$ 14,578	$ 16,000
Work in process	11,687	11,212
Finished goods	5,454	8,532
Total inventory	31,719	$ 35,744
DEFINITY
Inventory [Line Items]
Total inventory	$ 2,600

Property, Plant and Equipment_3

Property, Plant and Equipment, Net (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Property, Plant & Equipment [Line Items]
Property, plant & equipment, gross	$ 201,221		$ 201,221		$ 196,583
Less: accumulated depreciation and amortization	(82,728)		(82,728)		(76,412)
Total property, plant and equipment, net	118,493		118,493		120,171
Depreciation and amortization expense	3,200	$ 2,700	6,200	$ 5,700
Impairment of long-lived assets			0	$ 7,275
Land
Property, Plant & Equipment [Line Items]
Property, plant & equipment, gross	13,450		13,450		13,450
Buildings
Property, Plant & Equipment [Line Items]
Property, plant & equipment, gross	72,472		72,472		70,381
Machinery, equipment and fixtures
Property, Plant & Equipment [Line Items]
Property, plant & equipment, gross	83,758		83,758		77,854
Computer software
Property, Plant & Equipment [Line Items]
Property, plant & equipment, gross	24,110		24,110		23,644
Construction in progress
Property, Plant & Equipment [Line Items]
Property, plant & equipment, gross	$ 7,431		$ 7,431		$ 11,254

Business Combinations - Narrati

Business Combinations - Narrative (Details) $ in Thousands	Jun. 19, 2020USD ($)	Mar. 31, 2021USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2021USD ($)	Dec. 31, 2020USD ($)
Business Acquisition [Line Items]
Goodwill					$ 61,189	$ 58,632
Progenics
Business Acquisition [Line Items]
Purchase price	$ 419,009
Fair value of bridge loan settled at close	10,074
Measurement period adjustment		$ 2,600
Acquired contingent receivable	10,100
Goodwill	$ 45,475
Acquisition related costs			$ 7,500	$ 8,900
Progenics | Discount rate
Business Acquisition [Line Items]
Measurement input					0.230

Business Combinations - Fair Va

Business Combinations - Fair Value of the Consideration Transferred in the Acquisition (Details) - USD ($) $ in Thousands	Jun. 19, 2020	Jun. 30, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Fair value of contingent considerations (CVRs)		$ 43,800	$ 15,800
Progenics
Business Acquisition [Line Items]
Issuance of common stock	$ 398,110
Fair value of replacement options	7,125
Fair value of bridge loan settled at close	10,074
Fair value of contingent considerations (CVRs)	3,700
Total consideration transferred	$ 419,009

Business Combinations - Assets

Business Combinations - Assets and Liabilities (Details) - USD ($) $ in Thousands	Jun. 19, 2020	Jun. 30, 2021	Dec. 31, 2020
Business Combination Segment Allocation [Line Items]
Goodwill		$ 61,189	$ 58,632
Progenics
Business Combination Segment Allocation [Line Items]
Cash and cash equivalents	$ 15,421
Accounts receivable	5,787
Inventory	1,075
Other current assets	3,684
Property, plant and equipment	14,972
Identifiable intangible assets IPR&D	151,100
Other long-term assets	37,631
Accounts payable	(1,616)
Accrued expenses and other liabilities	(8,287)
Other long-term liabilities	(31,158)
Long-term debt and other borrowings	(40,200)
Deferred tax liabilities	(5,975)
Goodwill	45,475
Total consideration transferred	419,009
Progenics | Previously Reported
Business Combination Segment Allocation [Line Items]
Cash and cash equivalents	15,421
Accounts receivable	5,787
Inventory	915
Other current assets	3,250
Property, plant and equipment	14,972
Identifiable intangible assets IPR&D	150,900
Other long-term assets	37,631
Accounts payable	(1,616)
Accrued expenses and other liabilities	(8,207)
Other long-term liabilities	(30,778)
Long-term debt and other borrowings	(40,200)
Deferred tax liabilities	(3,717)
Goodwill	42,051
Total consideration transferred	419,009
Progenics | Revision of Prior Period, Adjustment
Business Combination Segment Allocation [Line Items]
Inventory	160
Other current assets	434
Identifiable intangible assets IPR&D	200
Accrued expenses and other liabilities	(80)
Other long-term liabilities	(380)
Deferred tax liabilities	(2,258)
Goodwill	3,424
Total consideration transferred	0
Currently marketed products | Progenics
Business Combination Segment Allocation [Line Items]
Identifiable intangible assets	$ 142,900
Identifiable intangible assets useful lives	15 years
Currently marketed products | Progenics | Previously Reported
Business Combination Segment Allocation [Line Items]
Identifiable intangible assets	$ 142,100
Currently marketed products | Progenics | Revision of Prior Period, Adjustment
Business Combination Segment Allocation [Line Items]
Identifiable intangible assets	800
Licenses | Progenics
Business Combination Segment Allocation [Line Items]
Identifiable intangible assets	$ 85,800
Identifiable intangible assets useful lives	11 years 6 months
Licenses | Progenics | Previously Reported
Business Combination Segment Allocation [Line Items]
Identifiable intangible assets	$ 87,500
Licenses | Progenics | Revision of Prior Period, Adjustment
Business Combination Segment Allocation [Line Items]
Identifiable intangible assets	(1,700)
Developed technology | Progenics
Business Combination Segment Allocation [Line Items]
Identifiable intangible assets	$ 2,400
Identifiable intangible assets useful lives	9 years
Developed technology | Progenics | Previously Reported
Business Combination Segment Allocation [Line Items]
Identifiable intangible assets	$ 3,000
Developed technology | Progenics | Revision of Prior Period, Adjustment
Business Combination Segment Allocation [Line Items]
Identifiable intangible assets	$ (600)

Business Combinations - Pro-For

Business Combinations - Pro-Forma (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2020USD ($)
Business Acquisition [Line Items]
Pro forma revenue	$ 167,619
Pro forma net loss	18,115
Progenics
Business Acquisition [Line Items]
Revenue from acquiree	1,000
Loss from acquiree	$ 3,200

Sale of Puerto Rico Subsidiar_2

Sale of Puerto Rico Subsidiary (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jan. 29, 2021	Dec. 31, 2020
Current assets
Total current assets	$ 0		$ 5,242
Current liabilities
Total current liabilities	0		1,793
Puerto Rican Radiopharmacy Servicing Subsidiary
Non-Current Liabilities:
Pre-tax book gain on disposal	$ 15,300
Disposed of by Sale | Puerto Rican Radiopharmacy Servicing Subsidiary
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal group consideration		$ 18,000
Disposal group holdback amount		1,800
Current assets
Cash and cash equivalents		540	941
Accounts receivable, net		1,959	2,191
Inventory		530	420
Other current assets		65	43
Total current assets		3,094	3,595
Non-Current Assets:
Property, plant & equipment, net		780	761
Intangibles, net		96	96
Other long-term assets		774	790
Total assets held for sale		4,744	5,242
Current liabilities
Accounts payable		185	224
Accrued expense and other liabilities		369	661
Total current liabilities		554	885
Non-Current Liabilities:
Asset retirement obligations		306	302
Other long-term liabilities		588	606
Total liabilities held for sale		$ 1,448	$ 1,793

Asset Retirement Obligations (D

Asset Retirement Obligations (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2021USD ($)
Asset Retirement Obligation Disclosure [Abstract]
Asset retirement obligation liabilities expected, present value	$ 26,400
Asset Retirement Obligation, Roll Forward Analysis [Roll Forward]
Asset retirement obligations, beginning balance	14,020
Accretion expense	777
Asset retirement obligations, ending balance	14,797
Financial assurance in form of surety bond	$ 28,200

Intangibles, Net - Schedule of

Intangibles, Net - Schedule of Intangibles, Net (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Indefinite lived, Cost	$ 15,640	$ 148,440
Total, Cost	490,102	489,945
Accumulated Amortization	(124,843)	(113,933)
Total	349,619
Total, Net	365,259	376,012
Trademarks
Finite-Lived Intangible Assets [Line Items]
Cost	13,540	13,540
Accumulated Amortization	(11,234)	(10,958)
Total	2,306	2,582
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Cost	97,022	96,865
Accumulated Amortization	(94,346)	(93,770)
Total	2,676	3,095
Currently marketed products
Finite-Lived Intangible Assets [Line Items]
Cost	275,700	142,900
Accumulated Amortization	(11,205)	(5,053)
Total	264,495	137,847
Licenses
Finite-Lived Intangible Assets [Line Items]
Cost	85,800	85,800
Accumulated Amortization	(7,781)	(4,008)
Total	78,019	81,792
Developed technology
Finite-Lived Intangible Assets [Line Items]
Cost	2,400	2,400
Accumulated Amortization	(277)	(144)
Total	$ 2,123	$ 2,256

Intangibles, Net - Additional I

Intangibles, Net - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Finite-Lived Intangible Assets [Line Items]
Amortization expense	$ 6.1	$ 0.9	$ 10.8	$ 1.3
IPR & D
Finite-Lived Intangible Assets [Line Items]
Decrease in indefinite lived assets			132.8
Currently marketed products
Finite-Lived Intangible Assets [Line Items]
Increase in finite lived assets			$ 132.8

Intangibles, Net - Schedule o_2

Intangibles, Net - Schedule of Expected Future Amortization Expense Related to Intangible Assets (Details) $ in Thousands	Jun. 30, 2021USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Remainder of 2021	$ 16,746
2022	33,233
2023	32,634
2024	32,563
2025	32,508
2026 and thereafter	201,935
Total	$ 349,619

Long-Term Debt, Net, and Othe_3

Long-Term Debt, Net, and Other Borrowings (Details) - USD ($)	Mar. 31, 2021	Jun. 30, 2021	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Debt Instrument [Line Items]
Remainder of 2021		$ 5,000,000	$ 5,000,000
2022		11,250,000	11,250,000
2023		15,000,000	15,000,000
2024		148,750,000	148,750,000
Total principal outstanding		180,000,000	180,000,000
Unamortized debt discount		(598,000)	(598,000)
Unamortized debt issuance costs		(516,000)	(516,000)
Finance lease liabilities		735,000	735,000
Total		179,621,000	179,621,000
Less: current portion		(10,372,000)	(10,372,000)
Total long-term debt, net and other borrowings		$ 169,249,000	169,249,000		$ 197,699,000
Gain on extinguishment of debt			$ 889,000	$ 0
2019 Term Loan Facility
Debt Instrument [Line Items]
Debt instrument term		5 years
Interest rate		2.40%	2.40%
Royalty-Backed Loan
Debt Instrument [Line Items]
Debt instrument face amount	$ 50,000,000
Extinguishment of debt	30,900,000
Prepayment of debt	500,000
Gain on extinguishment of debt	$ 900,000

Derivative Instruments (Detail)

Derivative Instruments (Detail) - USD ($)	Jun. 30, 2021	Dec. 31, 2020	Mar. 31, 2020
Derivative [Line Items]
Pre-tax deferred losses expected to be reclassified to earnings during the next 12 months	$ 700,000
Cash Flow Hedge | Interest Rate Swaps
Derivative [Line Items]
Notional amount			$ 100,000,000
Average fixed interest rate			0.82%
Cash Flow Hedge | Interest Rate Swaps | Accrued expenses and other liabilities
Derivative [Line Items]
Liabilities	$ 897,000	$ 1,908,000

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Loss (Detail) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive loss, tax	$ 200	$ 500
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	514,205	114,601
Other comprehensive income before reclassifications	695	(1,722)
Amounts reclassified to earnings	353	76
Ending balance	508,140	515,583
Foreign currency translation
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(630)	(960)
Other comprehensive income before reclassifications	296	(194)
Amounts reclassified to earnings	0	0
Ending balance	(334)	(1,154)
Unrealized loss on cash flow hedges
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(1,418)	0
Other comprehensive income before reclassifications	399	(1,528)
Amounts reclassified to earnings	353	76
Ending balance	(666)	(1,452)
Accumulated other comprehensive loss
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(2,048)	(960)
Ending balance	$ (1,000)	$ (2,606)

Stock-Based Compensation (Detai

Stock-Based Compensation (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 4,588	$ 3,385	$ 7,905	$ 6,460
Cost of goods sold
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	906	645	1,528	1,263
Sales and marketing
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	692	394	1,042	647
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	2,391	1,994	4,311	3,809
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 599	$ 352	$ 1,024	$ 741

Net (Loss) Income Per Common _3

Net (Loss) Income Per Common Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Earnings Per Share [Abstract]
Net loss	$ (26,657)	$ (7,012)	$ (17,649)	$ (3,675)
Basic weighted-average common shares outstanding (in shares)	67,505	43,135	67,300	41,284
Effect of dilutive stock options (in shares)	0	0	0	0
Effect of dilutive restricted stock (in shares)	0	0	0	0
Diluted weighted-average common shares outstanding (in shares)	67,505	43,135	67,300	41,284
Basic loss per common share (in dollars per share)	$ (0.39)	$ (0.16)	$ (0.26)	$ (0.09)
Diluted loss per common share (in dollars per share)	$ (0.39)	$ (0.16)	$ (0.26)	$ (0.09)
Antidilutive securities excluded from diluted net income per common share (in shares)	3,173	1,649	3,173	1,517

Other Income (Details)

Other Income (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Other Income and Expenses [Abstract]
Foreign currency (gains) losses	$ (13)	$ (94)	$ 29	$ 220
Tax indemnification income, net	(158)	(554)	(731)	(1,109)
Interest income	(11)	(105)	(28)	(214)
Other	0	(3)	(1)	(3)
Total other income	$ (182)	$ (756)	$ (731)	$ (1,106)

Commitments and Contingencies (

Commitments and Contingencies (Details)	1 Months Ended
	Oct. 31, 2015patent	Feb. 27, 2019EUR (€)
European
Loss Contingencies [Line Items]
Number of patents | patent	3
MIP
Loss Contingencies [Line Items]
Court deposit | €		€ 400,000

Segment Information (Details)

Segment Information (Details)	6 Months Ended
	Jun. 30, 2021segment
Segment Reporting [Abstract]
Operating segments	1